REG - Litigation Cap. Mgmt - Increase in Credit Facility and Waiver Extension

Litigation Capital ManagementAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260202:nRSB2024Ra&default-theme=true

RNS Number : 2024R  Litigation Capital Management Ltd  02 February 2026

2 February 2026

Litigation Capital Management Limited

("LCM" or the "Company")

Increase in Credit Facility and Covenant Waiver Extension

 

Litigation Capital Management Limited ("LCM"), an alternative asset manager
specialising in dispute financing solutions internationally, announces that it
has to increase its credit facility with funds managed by Northleaf Capital
Partners (Canada) Ltd ("Northleaf") from US$75 million to US$100 million.
Furthermore, the debt covenant waiver from Northleaf that was due to expire at
the end of January 2026 has been extended to 1 March 2026.  During the
extended waiver period the interest on the loan remains increased by 2.00% per
annum consistent with the initial waiver. There is no additional one-time
waiver fee in relation to this extension.

The Strategic Review that was first announced on 15 September 2025 continues
to progress and this waiver extension is reflective of Northleaf's ongoing
support while LCM works towards a long-term resolution of its capital
position. LCM management will provide an update on the progress of the
Strategic Review in due course.

 

 

Enquiries

 Litigation Capital Management
 Patrick Moloney, Chief Executive Officer

 David Collins, Chief Financial Officer

 Cavendish (Nomad and Broker)                               Tel: 020 7220 0500
 Jonny Franklin-Adams and Isaac Hooper (Corporate Finance)

 Tim Redfern (Corporate Broking)

 

www.lcmfinance.com (http://www.lcmfinance.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAPAFEFFKEFA



            Copyright 2019 Regulatory News Service, all rights reserved